Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma 
Welcome,         Profile    Billing    Logout  
 20 Diseases   3 Trials   3 Trials   450 News 


1234567»
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Trial completion date, Trial primary completion date:  Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease (clinicaltrials.gov) -  Mar 15, 2024   
    P4,  N=23, Recruiting, 
    In SH-SY5Y cell assays, sedanolide (EC50 Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Journal:  Effect of safinamide on morning-off phenomenon in elderly patients with Parkinson's disease (Pubmed Central) -  Jan 8, 2024   
    Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025 Our results suggest that safinamide administered in the evening can benefit elderly patients who experience wearing off, especially morning off, and non-motor symptoms.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Review, Journal:  Safinamide for pain management in patients with Parkinson's disease. (Pubmed Central) -  Dec 17, 2023   
    Based on the findings of the included studies, safinamide appears to relieve the overall pain burden. However, the lack of sufficient data for conducting a meta-analysis highlights the need for future studies to report mean pain scores and their standard deviations.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Clinical, Journal:  The Effects of Safinamide in Chinese and Non-Chinese Patients with Parkinson's Disease. (Pubmed Central) -  Dec 10, 2023   
    P3
    Safinamide was shown to improve PD symptoms and quality of life in different ethnic populations, without any treatment by race interaction. Further studies are warranted to investigate potential differences in a real-life situation.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Clinical, Journal:  The effects of safinamide according to gender in Chinese parkinsonian patients. (Pubmed Central) -  Nov 28, 2023   
    Safinamide was shown to improve PD symptoms and quality of life in both male and female Chinese patients. Possible differences in the response between genders need to be further studied in larger and different ethnic populations.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Journal:  Effectiveness and safety of safinamide in the Toledo Movement Disorders Unit. (Pubmed Central) -  Oct 30, 2023   
    The plasma safinamide pharmacokinetic profile observed in this study is in line with the published results in both Chinese and non-Asian populations. Safinamide has been shown to be effective and safe in improving motor fluctuations, motor symptoms and the subjective perception of disease severity in PD patients previously receiving rasagiline and in those receiving low-dose safinamide, all of which is accompanied by a good safety profile.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Preclinical, Journal:  Establishment of a sensitive UPLC-MS/MS method to quantify safinamide in rat plasma. (Pubmed Central) -  Sep 13, 2023   
    The method was validated to be stable and had low noise, short chromatographic run time, wide linear range, small sample volumes, low sample injection volumes, and high sensitivity. Therefore, it can be used in pharmacokinetics and preclinical and clinical studies.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Journal, Real-world evidence, Real-world:  Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy. (Pubmed Central) -  Sep 9, 2023   
    The SYNAPSES data related to Italian patients confirms the good safety profile of safinamide even in special groups of patients. Motor fluctuations and motor impairment improved at the follow-up suggesting the significant role of safinamide in managing motor symptoms in PD patients.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    SAFE-DBS  () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1542;    
    However, a need for levodopa reduction was found in the OP group. These first results indicate a non-significant trend towards greater motor and certain neuropsychiatric symptom reduction of safinamide in the perioperative period.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Efficacy and safety of safinamide in PD patients over 70 years vs. under 70 years old; () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1535;    
    No statistically significant differences were found regarding the safety and efficacy of safinamide between groups. However, this sample has shown that postural instability and cognitive symptoms may possibly predict safinamide
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Safinamide in Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_1526;    
    Long-term clinical benefit was confirmed in clinical practice. It is safe to use safinamide in an elderly population.
  • ||||||||||  Comtan (entacapone) / Novartis, Orion Corp, Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Dopamine dysregulation syndrome in Parkinson () -  Aug 30, 2023 - Abstract #MDSCongress2023MDS_Congress_613;    
    DDS is a rare but difficult to manage. We suggest the safinamide can be a way to control DDS through this case.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Preclinical, Journal:  Analgesic effect of safinamide mesylate in a rat model of neuropathic pain. (Pubmed Central) -  Aug 14, 2023   
    The present findings show that safinamide improves neuropathic pain in male CCI model rats. Further animal model research and pathological and molecular pharmacological investigations are warranted.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Journal:  Evaluation of developmental toxicity of safinamide in zebrafish larvae (Danio rerio). (Pubmed Central) -  Aug 9, 2023   
    Transcriptome analysis identified that safinamide exposure may disturb a variety of physiological processes such as neuroactive ligand-receptor interaction signaling pathway. In summary, our study reveals that safinamide may cause developmental defects in zebrafish larvae and provides insights into its toxic reactions in early develoment.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Neuroprotective potential of safinamide mesylate in streptozotocin induced sporadic Alzheimer (In-Person) -  Jul 6, 2023 - Abstract #AAIC2023AAIC_3990;    
    In the subgroups, findings were congruent with the total population, which allows the clinical utilisation of safinamide also in more vulnerable patient groups. Based on the outcomes of the current investigations it would be safe to conclude that safinamide mesylate has neuroprotective potential and the observed cognitive enhancement in STZ rats following safinamide mesylate treatment may be due to its antioxidant potential and its ability to protect or preserve neuronal cells.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Journal:  The effects of safinamide on dysphagia in Parkinson's disease. (Pubmed Central) -  May 29, 2023   
    In conclusion, a medicine for CDS may effectively improve swallowing functions in patients with PD. This is the first study to show that the MAOB inhibitor safinamide partly but significantly improves swallowing function in patients with PD.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Review, Journal:  Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations. (Pubmed Central) -  May 22, 2023   
    Here, we summarize current knowledge on both medication classes, with a focus on the added clinical value in Parkinson's disease. Furthermore, we outline practical considerations in the treatment of motor fluctuations and provide an outlook on ongoing studies with MAO-B and COMT inhibitors.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Review, Journal:  A comprehensive review of the docking studies of chalcone for the development of selective MAO-B inhibitors. (Pubmed Central) -  May 16, 2023   
    Here we focused on the interactions between reported chalcone derivatives and the active site of monoamine oxidase B and the influence of substitutions on those interactions. Detailed images illustrating the interactions and impact of the substituents or structural modifications on these interactions were used to support the docking results.
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma
    Enrollment open, Trial completion date, Trial primary completion date:  Effect of Safinamide on Sleep Quality in Patients With Parkinson's Disease (clinicaltrials.gov) -  Mar 30, 2023   
    P4,  N=23, Recruiting, 
    Thus, we identified that C14 may be a promising drug candidate for PD treatment. Unknown status --> Recruiting | Trial completion date: Apr 2021 --> Apr 2024 | Trial primary completion date: Apr 2021 --> Apr 2024
  • ||||||||||  Xadago (safinamide) / Meiji Seika, Eisai, Valeo Pharma, Zambon, Supernus Pharma, Ongentys (opicapone) / Ono Pharma, Neurocrine, BIAL
    Review, Journal:  Off-time Treatment Options for Parkinson's Disease. (Pubmed Central) -  Jan 13, 2023   
    The choice of the right/first add-on treatment is still a matter of debate as well as the proper time for an advanced therapy to be considered. In this narrative review, we discuss all the above cited aspects of MF in patients with PD, including their phenomenology, management, by means of pharmacological and advanced therapies, on-going clinical trials and future research and treatment perspectives.